Advertisement
Person › Details
Guy Braunstein (Actelion Ltd. (SIX: ATLN))
Braunstein, Guy (Actelion 201108 Head Clinical Development)
Organisation | Actelion Ltd. (SIX: ATLN) | |
Group | Johnson & Johnson (JnJ) (Group) | |
Product | Tracleer® | |
Product 2 | ponesimod | |
Record changed: 2021-10-12 |
Advertisement
More documents for Guy Braunstein
- [1] Idorsia Ltd.. (10/11/21). "Press Release: Idorsia Announces the Results of MODIFY, a Phase 3 Study of Lucerastat in Fabry Disease". Allschwil....
- [2] Idorsia Ltd.. (7/6/20). "Press Release: Idorsia Announces Positive Results in the Second Phase 3 Study of Daridorexant". Allschwil....
- [3] Idorsia Ltd.. (5/16/18). "Press Release: Idorsia Initiates MODIFY, a Phase 3 Registration Study to Assess Lucerastat as a Potential New Treatment Option for Patients with Fabry Disease". Allschwil....
- [4] Idorsia Ltd.. (7/28/17). "Press Release: ACT-541468 (DORA) Meets Primary Endpoint in Phase 2 Program in Adult and Elderly Patients with Insomnia". Allschwil....
- [5] Actelion Ltd.. (1/23/17). "Press Release: Actelion Announces Results of the MAESTRO Study with Macitentan in Patients with Pulmonary Arterial Hypertension Due to Eisenmenger Syndrome". Allschwil....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top